Five Prime Therapeutics prices IPO at $13, within the range

Comment

Shutterstock photo

Five Prime Therapeutics, which is developing protein therapeutics for cancers and autoimmune diseases, raised $62 million by offering 4.8 million shares at $13, within the range of $12 to $14. Five Prime Therapeutics plans to list on the NASDAQ under the symbol FPRX. Five Prime Therapeutics initially filed confidentially on 6/14/2013. Jefferies, BMO Capital Markets and Wells Fargo Securities acted as lead managers on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs


More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com